Mass General Brigham Ventures
Profile and portfolio
Mass General Brigham Ventures is the corporate venture arm of Mass General Brigham, a healthcare company. It was founded in 2008 and is based in Somerville, United States. It invests from seed to Series A. Sectors it names: biotech and life sciences, medical devices, healthcare and digital health.
- IPOsS2
- 8
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Seed to Series A |
| Sectors | Biotech and life sciences, Medical devices, Healthcare and digital health |
| Geography | North America |
| Offices | Somerville, United States |
Sources: S1 Mass General Brigham Ventures about.
Where it invests and who leads it
LeadersS3
- Roger KittermanManaging PartnerFind on LinkedInFirm page
- Carl BerkePartnerFind on LinkedInFirm page
- Meredith FisherPartnerFind on LinkedInFirm page
- Julius KnowlesPartnerFind on LinkedInFirm page
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Mass General Brigham | Single source | S3 |
| Parent industry | Healthcare and life sciences | Single source | S3 |
| Founded | 2008 | Single source | S1 |
| Headquarters | Somerville, United States | Single source | S4 |
| Status | Active | Single source | S1 |
| Capital source | Parent company only | Single source | S1 |
| Exits | 20 total, 8 IPOs | Single source | S2 |
| Stages | Seed, Series A | Single source | S1 |
Notable outcomes
IPOs and acquisitions of portfolio companies. Price shown only where published.
| Company | Type | Year | Acquirer or exchange | Source |
|---|---|---|---|---|
| Adheron Therapeutics | Acquisition | 2015 | Roche | S2 |
| Amolyt Pharma | Acquisition | 2024 | AstraZeneca | S2 |
| Annovation BioPharma | Acquisition | 2015 | The Medicines Company | S2 |
| CoStim Pharmaceuticals | Acquisition | 2014 | Novartis | S2 |
| LifeImage | Acquisition | 2022 | Intelerad Medical Systems | S2 |
| Lysosomal Therapeutics | Acquisition | 2020 | Bial Biotech | S2 |
| QPID Health | Acquisition | 2016 | eviCore Healthcare | S2 |
| Scorpion | Acquisition | 2025 | Eli Lilly | S2 |
| SeQure | Acquisition | 2025 | MaxCyte | S2 |
| Syntimmune | Acquisition | 2018 | Alexion | S2 |
For founders
Portfolio
The firm's portfolio page lists 19 companies.S2
Every company on the Mass General Brigham Ventures list
19 companies, as listed on the firm's own website: 10 exited, 9 listed.S2 Read the firm's list.
Exited 10
- Adheron Therapeutics
- Amolyt Pharma
- Annovation BioPharma
- CoStim Pharmaceuticals
- LifeImage
- Lysosomal Therapeutics
- QPID Health
- Scorpion
- SeQure
- Syntimmune
Listed 9
- Abcuro
- Affinia Therapeutics
- Amplifire
- Crosstalk Bio
- DexCare
- Falcon Bio
- InStride Health
- Nocion Therapeutics
- Violet Therapeutics
Fund vehicles
| Vehicle | Size | Year | Source |
|---|---|---|---|
| Artificial Intelligence and Digital Innovation Fund | USD 30M | 2020 | S6 |
History
- Mass General Brigham Ventures founded.S1
Official pages
Read the firm's own pages for current information.
Sources
- S1Mass General Brigham Ventures aboutFirm
- S2Mass General Brigham Ventures investment portfolioFirm
- S3Mass General Brigham Ventures teamFirm
- S4Contact the Mass General Brigham Ventures TeamFirm
- S5MIT Sloan: Carl Berke, Partner at Mass General Brigham VenturesPress
- S6Mass General Brigham: Venture Capital and InvestmentsFirm
- S7PitchBook: Mass General Brigham VenturesThird-party report
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by Mass General Brigham Ventures or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.